Ibaraki, Japan

Masahiro Asada

This inventor holds 6 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignees: National Institute of Advanced Industrial Science and Technology, Agency of Industrial Science and Technology. Active years: 2006-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiro Asada. Retrieved from https://idiyas.com/inventor/masahiro-asada-jpyhs825

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 16.7


Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 26(Granted Patents)


Location History:

  • Tsukuba, JP (2010 - 2011)
  • Ibaraki, JP (2006 - 2014)

Company Filing History:


Years Active: 2006-2014

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Masahiro Asada: Innovator in Pharmaceutical Composition and Receptor Activity

Introduction

Masahiro Asada is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceutical compositions and receptor activity, holding a total of 6 patents. His work focuses on innovative methods for screening substances that activate receptors associated with metabolic processes.

Latest Patents

One of Asada's latest patents is a method for screening a test substance for activating a receptor associated with FGF 21 activity. This invention utilizes betaKlotho or substances that modulate betaKlotho activity as agents for controlling FGF21 activity mediated by an FGF receptor. The pharmaceutical composition developed from this invention is particularly aimed at addressing anti-metabolic syndrome and controlling blood glucose levels. Additionally, Asada has developed a screening system for substances that enhance or suppress betaKlotho activity, utilizing a cell system that expresses an FGF receptor and/or betaKlotho on its surface.

Another significant patent involves an isolated mutant protein of fibroblast growth factor 18. This mutant protein has altered fibroblast growth factor receptor specificity, achieved by deleting one or more amino acid residues from the N-terminus of the naturally secreted fibroblast growth factor 18. This protein mutant can be utilized in pharmaceutical compositions aimed at regulating hair regeneration or growth, as well as bone or cartilage formation.

Career Highlights

Asada has worked with esteemed organizations such as the National Institute of Advanced Industrial Science and Technology and the Agency of Industrial Science and Technology. His career reflects a commitment to advancing scientific knowledge and developing practical applications for his inventions.

Collaborations

Throughout his career, Asada has collaborated with notable colleagues, including Toru Imamura and Masashi Suzuki. These partnerships have contributed to the success and impact of his innovative work.

Conclusion

Masahiro Asada's contributions to the field of pharmaceutical compositions and receptor activity demonstrate his dedication to innovation and scientific advancement. His patents reflect a deep understanding of metabolic processes and the potential for therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…